Adjuvant endocrine therapy
-
Ebook Breast cancer management for surgeons: Part 2 includes content: Speciic autologous flap techniques, goldilocks procedure, nipple reconstruction, complications of breast surgery and their management, adjuvant endocrine therapy, adjuvant chemotherapy, hereditary breast cancer,… and other contents. Invite you to consult the details.
394p longtimenosee03 01-02-2024 1 0 Download
-
The adjuvant treatment with Aromatase Inhibitor (AI) is considered standard of care for postmenopausal breast cancer (BC) women with hormone receptor-positive (HR+), however, it often causes adverse effects such as cancer-related fatigue (CRF).
20p vialfrednobel 23-12-2023 4 3 Download
-
Tamoxifen is one of the fundamental pillars of adjuvant endocrine therapy for hormone receptor-positive breast cancer; however, 30–50% of patients receiving tamoxifen experience tumor relapse. This study aimed at determining the frequencies of the most clinically relevant CYP2D6 alleles and evaluating their impact on the respon‑siveness to tamoxifen in a cohort of Syrian breast cancer patients.
11p vialfrednobel 23-12-2023 6 3 Download
-
Extending adjuvant endocrine therapy (ET) beyond the standard 5 years ofers added protection against late breast cancer recurrences in women with early-stage hormone receptor-positive (HR+) breast cancer. Little is known about treatment persistence to extended ET (EET) and the role that genomic assays may play. In this study, we evaluated persistence to EET in women who had Breast Cancer Index (BCI) testing.
9p vioracle 29-09-2023 4 2 Download
-
Adjuvant endocrine treatment is essential for treating luminal subtypes of breast cancer, which constitute 75% of all breast malignancies. However, the detrimental side effects of treatment make it difficult for many patients to complete the guideline-required treatment.
12p vioracle 29-09-2023 6 3 Download
-
The National Comprehensive Cancer Network recommends that patients with hormone receptorpositive early breast cancer be considered for adjuvant endocrine therapy (ET) after primary treatment like surgical excision.
10p vikolindagrabar 27-07-2022 3 1 Download
-
Adjuvant endocrine therapy can improve disease-free survival and time before recurrence in breast cancer patients. However, it is associated with considerable side effects that negatively affect patients’ quality of life and cause non-adherence.
10p vijennie2711 29-09-2020 17 1 Download
-
Resistance towards endocrine therapy is a great concern in breast cancer treatment and may partly be explained by the activation of compensatory signaling pathways. The aim of the present study was to investigate if the insulin-like growth factor-1 receptor (IGF1R) signaling pathway was activated or deregulated in breast cancer patients and to explore if any of the markers were prognostic, with or without adjuvant tamoxifen.
13p vilisa271 22-09-2020 11 0 Download
-
Patients with luminal HER2-negative tumours have a favourable prognosis. However, there is a subpopulation in which poorer outcomes are obtained with endocrine therapy alone. This subpopulation is considered to benefit from chemotherapy. However, the significance of chemotherapy for those with luminal tumours has decreased due to recent changes in treatment strategies.
7p vilisa271 22-09-2020 10 1 Download
-
Bcl-2 plays an anti-apoptotic role, resulting in poor clinical outcome or resistance to therapy in most tumor types expressing Bcl-2. In breast cancer, however, Bcl-2 expression has been reported to be a favorable prognostic factor.
11p vimoscow2711 29-08-2020 8 0 Download
-
Ovarian function suppression (OFS) has been shown to be effective as adjuvant endocrine therapy in premenopausal women with hormone receptor-positive breast cancer. However, it is currently unclear if addition of OFS to standard tamoxifen therapy after completion of adjuvant chemotherapy results in a survival benefit.
7p vinaypyidaw2711 26-08-2020 12 2 Download
-
This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. Methods: This retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and immunohistochemical staining was done to assess the KIBRA expression.
11p vibaku2711 22-07-2020 14 1 Download
-
Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other proliferation markers, like Cyclin D1, and mitotic count can also be used to identify those estrogen receptor α (ERα) positive breast cancer patients that derive benefit from tamoxifen is not well established.
11p vimanila2711 29-06-2020 13 0 Download
-
Adjuvant endocrine therapy (AET) significantly decreases the risk of breast cancer recurrence and mortality. Notwithstanding the demonstrated efficacy of AET, 31–73% of breast cancer survivors do not persist with AET.
13p vimanila2711 29-06-2020 4 0 Download
-
Breast cancer is the most common malignancy in women worldwide. Although the endocrine therapy that targets estrogen receptor α (ERα) signaling has been well established as an effective adjuvant treatment for patients with ERα-positive breast cancers, long-term exposure may eventually lead to the development of acquired resistance to the anti-estrogen drugs, such as fulvestrant and tamoxifen.
13p vimanila2711 29-06-2020 8 0 Download
-
Several trials evaluated the role of ovarian function suppression for the adjuvant treatment of premenopausal patients with hormone receptor-positive early breast cancer.
11p vimanila2711 25-06-2020 11 1 Download
-
Adjuvant endocrine therapy undoubtedly prolongs the time to recurrence for patients with hormone-positive early breast cancer. Extended endocrine therapy to 10 years or longer has been expected to bring a greater clinical advantage. However, the related research conclusions are controversial.
11p vimanila2711 25-06-2020 14 1 Download
-
There are racial/ethnic disparities in breast cancer mortality may be attributed to differences in receipt of adjuvant cancer treatment. Our purpose was to determine whether the mortality disparities could be explained by racial/ethnic differences in long-term adherence to adjuvant endocrine therapy (AET).
12p viputrajaya2711 22-06-2020 10 0 Download
-
The aim of this study was to evaluate the prognostic potential of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) tumor tissue levels and examine the association between these biomarkers and classical prognostic factors in early node-negative luminal breast cancer patients.
13p viputrajaya2711 22-06-2020 5 0 Download